Search | Engineering

Subscribe Submit

Home Journals Focus Achievement Fronts About Us 中文版

Resource Type

Journal Article 2

Year

2020 1

2013 1

Keywords

multiple myeloma 2

thalidomide 2

1p32.3 deletion 1

1q21 gain 1

FISH 1

bortezomib 1

lymphoma 1

prognosis 1

open ︾

Search scope:

排序： Display mode:

Therapeutic effects of thalidomide in hematologic disorders: a review

Miao Xu, Yu Hou, Lei Sheng, Jun Peng

Frontiers of Medicine 2013, Volume 7, Issue 3, Pages 290-300 doi: 10.1007/s11684-013-0277-z

Abstract:

The extensive autoimmune, anti-inflammatory, and anticancer applications of thalidomide have inspiredAs an inexpensive agent with relatively low toxicity, thalidomide is regarded as a promising therapeuticAside from optimal outcomes, the toxicities and adverse effects of thalidomide should also be examinedcurrent work includes a discussion of the mechanisms through which the novel biological effects of thalidomideWith appropriate safeguards, thalidomide may benefit patients suffering from a broad variety of disorders

Keywords： thalidomide multiple myeloma lymphoma

HTML PDF Collect

Clinical characteristics and prognostic values of 1p32.3 deletion detected through fluorescence

Huanping Wang, Haitao Meng, Jinghan Wang, Yinjun Lou, Yile Zhou, Peipei Lin, Fenglin Li, Lin Liu, Huan Xu, Min Yang, Jie Jin

Frontiers of Medicine 2020, Volume 14, Issue 3, Pages 327-334 doi: 10.1007/s11684-019-0712-x

Abstract: patients with newly diagnosed MM; among which, 270 received bortezomib-based therapies, and 141 received thalidomide-basedUnivariate analysis showed that patients with del(1p32.3) under thalidomide-based therapies (median PFSremained a powerful independent factor with worse PFS ( = 0.006) and OS ( = 0.016) for patients under thalidomide-basedIn conclusion, del(1p32.3) is associated with short PFS and OS in patients with MM who received thalidomide

Keywords： 1p32.3 deletion 1q21 gain prognosis multiple myeloma FISH bortezomib thalidomide